At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
Sargramostim +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial Evaluating the Safety and Efficacy of Plerixafor and Sargramostim (GM-CSF) for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal, HLA-Matched Allogeneic Sibling Donors
In Brief
A Phase 2 clinical trial evaluating Sargramostim and Plerixafor for Leukemia, Myeloid, Acute and 5 related conditions. Completed, enrolled 48 participants across 1 site.
Detailed Summary
This study will gather information about the combination the drugs plerixafor with sargramostim in donors of blood-forming cells (stem cells). These stem cells will be collected from the donor and transplanted into their sibling. The investigators believe that the two drugs together will provide enough stem cells for transplantation and may also reduce the risk of graft versus host disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Multiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartApr 2011
Primary CompletionJan 2014
Study CompletionDec 2016
TodayJul 2026
First PostedJul 8, 2010
Enrollment StartApr 1, 2011
Primary CompletionJan 15, 2014
Study CompletionDec 31, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.0 years ago
Interventions
Sargramostimdrug
Plerixafordrug